Differentially Expressed Genes Identify FIGO Stage II Cervical Cancer Patients with a Higher Risk of Relapse in a Small Cohort.

ABSTRACT: Background/Objectives: Most studies investigating prognostic biomarkers in cervical cancer (CC) analyze patients irrespective of FIGO stage, potentially masking molecular features that underlie the aggressiveness of some FIGO II tumors. To address this, we investigated differential gene expression in a FIGO II CC cohort to identify a gene signature predictive of progression-free survival (PFS) within five years of treatment initiation. Methods: Tumor samples from 15 CC patients were analyzed using RNA sequencing, bioinformatics, and machine learning to identify differentially expressed genes (DEGs) associated with prognosis. Findings were validated in an independent CC cohort (n = 174). Results: High expression of B3GALT1 (HR = 5.11), GTF3C2-AS1 (HR = 18.73), an

SUBMITTER: Melo CPS 

PROVIDER: S-EPMC12565686 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature